Results 11 to 20 of about 11,630 (189)

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

open access: yesHepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai   +29 more
wiley   +1 more source

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma

open access: yesCancer Medicine, 2021
Antiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited.
Masahiro Nishikawa   +15 more
doaj   +1 more source

The impact of parental death on the timing of first marriage: Evolutionary versus social explanations (The Netherlands, 1850-1940)

open access: yesDemographic Research, 2019
Background: This article examines the impact of parental death in childhood, adolescence, and adulthood on male and female age at marriage in the Netherlands in the period 1850-1940.
Matthias Rosenbaum-Feldbrügge   +1 more
doaj   +1 more source

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

open access: yesBMC Cancer, 2020
Background It is not known what combination of bevacizumab and chemotherapy agents is the best therapeutic regimen. Comparative study results among the efficacies of bevacizumab plus chemotherapy remain controversial in patients with HER2-negative ...
Zhengwu Sun   +4 more
doaj   +1 more source

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map

open access: yesBMC Cancer, 2023
Background Glioblastoma (GBM) is the most malignant primary tumor in the brain, with poor prognosis and limited effective therapies. Although Bevacizumab (BEV) has shown promise in extending progression-free survival (PFS) treating GBM, there is no ...
Minjie Fu   +7 more
doaj   +1 more source

Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience

open access: yesFrontiers in Oncology, 2020
This study aimed to determine the real-world, long-term prognostic impacts, and adverse effects (AEs) of bevacizumab (BEV) in Asian patients with ovarian/tubal/peritoneal cancers.
Pei-Ying Wu   +7 more
doaj   +1 more source

Establishment and application of multiplex droplet digital polymerase chain reaction assay for bovine enterovirus, bovine coronavirus, and bovine rotavirus

open access: yesFrontiers in Veterinary Science, 2023
Bovine enterovirus (BEV), bovine coronavirus (BCoV), and bovine rotavirus (BRV) are still the major worldwide concerns in the health care of cattle, causing serious economic losses in the livestock industry.
Junzhen Chen   +10 more
doaj   +1 more source

ISCAD — Design, control and car integration of a 48 volt high performance drive

open access: yesCES Transactions on Electrical Machines and Systems, 2019
Through its new technology the ISCAD system provides up to 300 kW with a safe-to-touch 48 Volt battery. This results in a high-performance drive that is intrinsically electrically safe. The novel machine design requires new concepts for power electronics,
S. Runde   +4 more
doaj   +1 more source

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance

open access: yesFrontiers in Pharmacology, 2022
At present, treatment options for osimertinib resistance are very limited. Dual inhibition of the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) significantly improved the progression-free survival (PFS) of advanced
Qingli Cui   +6 more
doaj   +1 more source

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

open access: yesCNS Oncology, 2019
Aim: Long-term survivors (LTS) after glioma recurrence while on bevacizumab (Bev) therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS ...
Liang Yen Liu   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy